This was forwarded by the leader of my local support group:
Dear XXX,
I’m writing today with an important update about Intrommune Therapeutics in my capacity as a company co-founder and advisor. The company is pleased to share with you that they have launched a crowdfunding campaign! This campaign will support the next steps of development for INT-301, an oral mucosal immunotherapy (OMIT) product for the long-term treatment of peanut allergy using a proprietary daily use toothpaste.
As always, it is important to the Intrommune team that the OMIT development pipeline truly addresses the needs of people with food allergies. This campaign helps the company continue to prioritize these efforts. Would it be possible for you to share the campaign with your members and networks, and to encourage them to share it as well?
The full details of the campaign are here:
https://netcapital.com/ companies/intrommune
Over the past two years, Intrommune Therapeutics has licensed the rights to develop OMIT for food allergy and laid the groundwork for a research program to support the development of INT-301. With the proceeds of this campaign, the company plans to file for investigational new drug (IND) status for INT-301 with the FDA and plan for the future development of OMIT for food allergies. Submitting an IND application paves the way for starting clinical trials for peanut allergy OMIT.
You can find out more about Intrommune Therapeutics here:
http://www.intrommune.com/ Thank you for your interest and support! If you have any questions at all about the company, please reach out, and I will help as I can or connect you to my colleagues.
Sincerely,
Michelle Mantia
--
Michelle Mantia
Operations Manager
Intrommune Therapeutics
20 West 125th Street, Suite #1
New York, NY 10027 USA
e: mmantia@intrommune.com
w:
www.intrommune.com